Filing Flows › Haemonetics (HAE) › Q1 FY27 › vs Q4 FY26
Haemonetics (HAE) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Haemonetics's revenue fell $7.0M (-2%) from $346M in Q4 FY26 to $339M in Q1 FY27. Gross margin 59.8% against 57.2% (+2.5 pts).
Haemonetics, Q1 FY27: revenue $339M (+6% year over year), operating margin 16.9%, net earnings $33.0M, operating cash flow $52.3M. The chart draws each line against Q4 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q4 FY26 | Change | |
|---|---|---|---|
| Gross margin | 59.8% | 57.2% | +2.5 pts |
| Operating margin | 16.9% | -6.6% | +23.6 pts |
| Net margin | 9.7% | -5.8% | +15.5 pts |
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $339M | $346M | −$7.0M | -2% |
| Gross profit | $203M | $198M | $4.6M | +2% |
| Cost of revenue | $137M | $148M | −$11.6M | -8% |
| Operating profit | $57.5M | −$23.0M | $80.5M | — |
| Operating expenses | $145M | $221M | −$75.9M | -34% |
| Pre-tax earnings | $47.6M | −$28.4M | $76.0M | — |
| Other expense, net | $9.9M | $5.4M | $4.5M | +84% |
| Research & development | $16.2M | $14.4M | $1.8M | +12% |
| SG&A | $119M | $121M | −$2.0M | -2% |
| Other operating costs | $10.2M | $85.9M | −$75.7M | -88% |
| Net earnings | $33.0M | −$20.1M | $53.2M | — |
| Income tax | $14.6M | −$8.3M | $22.8M | — |
| Depreciation & amortization | $27.1M | $27.3M | −$208K | -0.8% |
| Share-based compensation | $9.3M | $9.1M | $184K | +2% |
| Working capital & other | $17.1M | −$54.6M | $71.8M | — |
| Operating cash flow | $52.3M | $70.9M | −$18.6M | -26% |
Questions
How much did Haemonetics's revenue grow quarter over quarter in Q1 FY27?
Haemonetics's revenue fell $7.0M (-2%) from $346M in Q4 FY26 to $339M in Q1 FY27. Gross margin 59.8% against 57.2% (+2.5 pts).